CDKN2A and retinoblastoma: Chromatin immunoprecipitation assays revealed that HMGA2 promoter was indeed decorated with H3K79 methylation marks in vehicle-treated Y79 cells, which were dramatically reduced by EPZ5676 treatment in contrast to the case of CDKN2A shown as a repressed gene promoter in RB cells (Fig. 4a, b).